FINANCIAL INFORMATION

Gain on Sale of Available-for-sale Securities

The gain on sale of available-for-sale securities was less than US$0.1 million for the year ended
December 31, 2017, compared to a loss of US$1.4 million for the year ended December 31, 2016.

Other Income(Expense), Net

Other income (expense), net increased by US$20.7 million to US$21.1 million for the year ended
December 31, 2017, from US$0.4 million for the year ended December 31, 2016. The increase was
mainly attributable to government grants and subsidies received and recognized.

Income Tax Expense

Income tax expense was US$30.7 million for the year ended December 31, 2017 compared with
US$0.1 million for the year ended December 31, 2016. In the year ended December 31, 2017, the
income tax expense was mainly attributable to income tax expense associated with BeiGene HK’s
contribution of BeiGene Shanghai to BeiGene Biologics and the tax due on the receipt of a related
government grant. These expense increases were partially offset by income tax benefit due to the
effect of estimated realized research and development tax credits and the U.S. Orphan Drug Credit for
our U.S. operating subsidiary.

Taxation

Cayman Islands

The Company is incorporated in the Cayman Islands. Under the current laws of the Cayman
Islands, the Company is not subject to income tax for the three months ended March 31, 2018 and 2017
and for the years ended December 31, 2017 and 2016.

United States

BeiGene (USA), which was incorporated in Delaware, United States on July 8, 2015, is subject
to statutory U.S. federal corporate income tax at a rate of 21% for the three months ended March 31,
2018 and 35% for the three months ended March 31, 2017 and for the years ended December 31, 2017
and 2016. BeiGene (USA) is also subject to the state income tax in New Jersey, California and
Massachusetts, at a rate of 9.0%, 8.8% and 8.0%, respectively, for the three months ended March 31,
2018 and 2017 and for the years ended December 31, 2017 and 2016. The corporate tax rate in the
United States changed to 21% for purposes of calculating the estimated tax expense for the twelve
months ended December 31, 2018.

— 277 —

